Abstract

ObjectiveGlucagon-like peptide-1 receptor agonists (GLP-1RAs) are used as anti-diabetic drugs and are approved for obesity treatment. However, GLP-1RAs also affect heart rate (HR) and arterial blood pressure (ABP) in rodents and humans. Although the activation of GLP-1 receptors (GLP-1R) is known to increase HR, the circuits recruited are unclear, and in particular, it is unknown whether GLP-1RAs activate preproglucagon (PPG) neurons, the brain source of GLP-1, to elicit these effects. MethodsWe investigated the effect of GLP-1RAs on heart rate in anaesthetized adult mice. In a separate study, we manipulated the activity of nucleus tractus solitarius (NTS) PPG neurons (PPGNTS) in awake, freely behaving transgenic Glu-Cre mice implanted with biotelemetry probes and injected with AAV-DIO-hM3Dq:mCherry or AAV-mCherry-FLEX-DTA. ResultsSystemic administration of the GLP-1RA Ex-4 increased resting HR in anaesthetized or conscious mice, but had no effect on ABP in conscious mice. This effect was abolished by β-adrenoceptor blockade with atenolol, but unaffected by the muscarinic antagonist atropine. Furthermore, Ex-4-induced tachycardia persisted when PPGNTS neurons were ablated, and Ex-4 did not induce expression of the neuronal activity marker cFos in PPGNTS neurons. PPGNTS ablation or acute chemogenetic inhibition of these neurons via hM4Di receptors had no effect on resting HR. In contrast, chemogenetic activation of PPGNTS neurons increased resting HR. Furthermore, the application of GLP-1 within the subarachnoid space of the middle thoracic spinal cord, a major projection target of PPG neurons, increased HR. ConclusionsThese results demonstrate that both systemic application of Ex-4 or GLP-1 and chemogenetic activation of PPGNTS neurons increases HR. Ex-4 increases the activity of cardiac sympathetic preganglionic neurons of the spinal cord without recruitment of PPGNTS neurons, and thus likely recapitulates the physiological effects of PPG neuron activation. These neurons therefore do not play a significant role in controlling resting HR and ABP but are capable of inducing tachycardia and so are likely involved in cardiovascular responses to acute stress.

Highlights

  • Glucagon-like peptide-1 (GLP-1) is best known as an incretin that is released from the gut into the bloodstream postprandially and enhances insulin secretion

  • We recently showed that selective activation of PPG neurons in the nucleus tractus solitarius (PPGNTS) neurons with chemogenetic methods produces a suppression of food consumption and that their activity is necessary for stress-induced suppression of feeding [8]

  • We demonstrate that GLP-1 receptors (GLP-1R) activation in the spinal cord is sufficient to elicit tachycardic responses and we found that PPGNTS neurons are capable of increasing resting heart rate (HR) but not arterial blood pressure (ABP)

Read more

Summary

Introduction

Glucagon-like peptide-1 (GLP-1) is best known as an incretin that is released from the gut into the bloodstream postprandially and enhances insulin secretion. GLP-1 receptor agonists (GLP-1RAs), such as exendin-4 (Ex-4), are in clinical use to treat type 2 diabetes mellitus. Both animal studies and clinical observations have established that GLP-1RAs have cardiovascular effects, including an increase in heart rate (HR) [1e7]. GLP-1 is produced within the brain, and there it is involved primarily in the regulation of food intake, and in stress responses [8e 16]. Food intake, anxiety-like behaviour, corticosterone levels, and sympathetic activity are all modulated in response to challenges to survival, including acute stress [17e19] with GLP-1 being implicated in the modulation of all these functions. GLP-1 suppresses food and water consumption, decreases reward, drives anxiety-like behaviour, activates the hypothalamic-pituitary-adrenal

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call